Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes

Howard J. Lee Jr†, Meghan W. Macomber2†, Matthew B. Spraker2, Stephen R. Bowen2, Daniel S. Hippe3, Angela Fung4, Kenneth J. Russell2, George E. Laramore2, Ramesh Rengan2, Jay Liao3, Smith Apisarnthanarax2 and Jing Zeng2*

Abstract

Background: We report prospectively captured clinical toxicity and patient reported outcomes in a single institutional cohort of patients treated for prostate cancer with proton beam therapy (PBT). This is the largest reported series of patients treated mostly with pencil beam scanning PBT.

Methods: We reviewed 231 patients treated on an IRB approved institutional registry from 2013 to 2016; final analysis included 192 patients with > 1-year of follow-up. Toxicity incidence was prospectively captured and scored using CTCAE v4.0. International Prostate Symptoms Score (IPSS), Sexual Health Inventory for Men (SHIM) score, and Expanded Prostate Cancer Index Composite (EPIC) bowel domain questionnaires were collected at each visit. Univariate Cox regression was used to explore associations of grade 2+ toxicity with clinical, treatment, and dosimetric variables.

Results: Median follow-up was 1.7 years. Grade 3 toxicity was seen in 5/192 patients. No grade 4 or 5 toxicity was seen. Patient reported quality-of-life showed no change in urinary function post-radiation by IPSS scores. Median SHIM scores declined by 3.7 points at 1-year post-treatment without further decrease beyond year 1. On univariate analysis, only younger age (HR = 0.61, p = 0.022) was associated with decreased sexual toxicity. EPIC bowel domain scores declined from 96 at baseline (median) by an average of 5.4 points at 1-year post-treatment (95% CI: 2.5–8.2 points, p < 0.001), with no further decrease over time. Bowel toxicity was mostly in the form of transient rectal bleeding and was associated with anticoagulation use (HR = 3.45, p = 0.002).

Conclusions: Grade 3 or higher toxicity was rare at 2-years after treatment with PBT for localized prostate cancer. Longer follow-up is needed to further characterize late toxicity and biochemical control.

Trial registration: NCT, NCT01255748. Registered 1 January 2013.

Keywords: Prostate cancer, Proton therapy, Quality of life, Patient reported outcomes

* Correspondence: jzeng13@uw.edu
† Howard J. Lee Jr and Meghan W. Macomber contributed equally to this work.
2 Department of Radiation Oncology, University of Washington School of Medicine, 1959 NE Pacific Street, Campus, Box 356043, Seattle, WA 98195, USA

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Numerous treatment options exist for localized prostate cancer. External beam radiation therapy is a non-invasive option that has shown similar disease control rates compared to other approaches such as radical prostatectomy and brachytherapy [1–5], and treatment modality choice is generally a consideration of side effect profile and shared decision making.

Dose escalation has been shown to improve cancer control in prostate cancer [6]. Delivering the high radiotherapy doses to the prostate necessary to improve outcomes can be challenging due to tolerance of surrounding organs at risk, in particular rectum and bladder. Higher radiation doses using conventional external beam techniques have been shown in several retrospective studies to increase the risk of late treatment related toxicity [7, 8]. Proton beam therapy (PBT) has emerged as an external beam radiotherapy treatment option. The unique dosimetric characteristics of PBT allow for dose escalation while reducing dose to surrounding structures, especially in the low-dose bath [7].

While numerous studies have demonstrated this reduction in low dose bath to surrounding normal tissues such as rectum and bladder, the clinical advantage remains unclear [8]. Only a few centers have reported clinical outcomes of patients treated with PBT for prostate cancer [9–18]. Existing proton literature in prostate cancer is mostly based on passive scattering proton technology, while pencil beam scanning (PBS) has some dosimetric advantages [19]. We present our 2-year outcomes regarding toxicity and patient reported quality of life (QOL) for patients receiving PBT at our institution. To our knowledge, this is the largest reported series of patients treated mostly with PBS proton technology.

Methods
Patient details and data collection
We reviewed 231 patients treated consecutively at our institution with PBT for localized prostate cancer on a prospective IRB-approved registry. Patients were excluded for prior radical prostatectomy, prior radiotherapy, treatment with mixed photon and proton radiation, or follow-up < 1-year. Total 192 patients were included in this analysis. Baseline characteristics are outlined in Table 1. All patients underwent institutional pathology review of prostate biopsy to confirm Gleason score. Intermediate risk patients by D’Amico risk groups underwent computed tomography (CT) and/or magnetic resonance imaging (MRI) of the pelvis. Patients with high-risk disease also had technetium bone scans.

Table 1 Patient characteristics

| Variable                        | No. (%) or Median (Range) |
|---------------------------------|---------------------------|
| Age, years                      | 68 (50–85)                |
| Race and ethnicity              |                           |
| African-American                | 3 (1.6%)                  |
| Asian                           | 4 (2.1%)                  |
| Hispanic                        | 2 (1.0%)                  |
| White                           | 176 (91.7%)               |
| Unknown                         | 7 (3.6%)                  |
| T stage                         |                           |
| T1                              | 104 (54.2%)               |
| T2a                             | 49 (25.5%)                |
| T2b                             | 25 (13.0%)                |
| T2c                             | 4 (2.1%)                  |
| T3-T4                           | 10 (5.2%)                 |
| PSA, ng/ml                      | 7.2 (1.6–69.6)            |
| Gleason score                   |                           |
| 6                               | 42 (21.9%)                |
| 7 = 3 + 4                       | 80 (41.7%)                |
| 7 = 4 + 3                       | 36 (18.8%)                |
| 8                               | 14 (7.3%)                 |
| 9–10                            | 20 (10.4%)                |
| Risk category                   |                           |
| Low                             | 38 (19.8%)                |
| Intermediate                    | 104 (54.2%)               |
| High                            | 50 (26.0%)                |
| Baseline IPSS Bother score†      | 2 (0–7)                   |
| Baseline IPSS score†             | 6 (0–28)                  |
| Baseline EPIC bowel domain score† | 96 (61–100)              |
| Baseline SHIM scoreab          | 18 (0–25)                 |
| Comorbidities                   |                           |
| History of diabetes             | 19 (9.9%)                 |
| History of hypertension         | 96 (50.0%)                |
| History of inflammatory bowel disease | 2 (1.0)       |
| History of hemorrhoids          | 26 (13.5%)                |
| Smoking statusa                 |                           |
| Never                           | 103 (57.5%)               |
| Former                          | 65 (36.3%)                |
| Current                         | 11 (6.1%)                 |
| Aspirin use                     | 74 (38.5%)                |
| Anticoagulant use               | 22 (11.5%)                |
| Pre-treatment urologic function |                           |
| Alpha blocker use               | 37 (19.3%)                |
| Alpha reductase inhibitor use    | 14 (7.3%)                 |
| TURP                            | 9 (4.7%)                  |

Outcome and follow up
All patients were evaluated at pre-treatment, weekly on-treatment, and every 3–4 months for the first year post-treatment, then at 6-month intervals. Acute toxicity
was defined as from start of radiation therapy to 90 days after treatment completion, and late toxicity was defined as at any time after 90 days. Patients prospectively completed International Prostate Symptoms Score (IPSS), Sexual Health Inventory for Men (SHIM) score, and Expanded Prostate Cancer Index Composite (EPIC) bowel domain questionnaires. Toxicity was scored using Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE).

**Table 1** Patient characteristics (Continued)

| Variable                        | No. (%) or Median (Range) |
|---------------------------------|---------------------------|
| Androgen deprivation therapy    | 71 (37.0%)                |
| Low risk                        | 1/71 (1.4%)               |
| Intermediate risk               | 27/71 (38.0%)             |
| High risk                       | 43/71 (60.6%)             |
| Pencil beam vs. uniform scanning| 144 vs 48 (75.0% vs 25%)  |
| Number of fields/day            |                           |
| 1                               | 92 (48%)                  |
| 2                               | 100 (52%)                 |
| Whole pelvis radiation          | 19 (9.9%)                 |
| US-based prostate volume, cm³   | 40 (12–100)               |

*aBased on patients not receiving androgen deprivation therapy (n = 121)

**Table 2** Patient dosimetry (N = 192)

| Variable                        | No. (%) or Median (Range) |
|---------------------------------|---------------------------|
| Dose                            |                           |
| < 79.2 Gy (RBE)                 | 27 (14.1%)                |
| ≥ 79.2 Gy (RBE)                 | 165 (85.9%)               |
| DVH Parameters                  |                           |
| Rectal wall V50, %              | 30.7 (8.0–56.6)           |
| Rectal wall V75, %              | 16.2 (0.0–30.6)           |
| Rectum V50, %                   | 18.6 (2.0–39.4)           |
| Rectum V70, %                   | 9.2 (0.0–34.7)            |
| Bladder wall V47, %             | 19.0 (6.8–56.7)           |
| Bladder wall V75, %             | 11.5 (0.0–37.0)           |
| Bladder V50, %                  | 11.8 (2.1–58.5)           |
| Bladder V75, %                  | 5.1 (0.0–35.5)            |
| Femoral head mean dose          |                           |
| Right, Gy                       | 25.8 (15.4–41.1)          |
| Left, Gy                        | 25.1 (11.3–39.9)          |
| Femoral head max dose           |                           |
| Right, Gy                       | 35.6 (27.5–60.4)          |
| Left, Gy                        | 35.6 (27.8–63.6)          |
| Penile bulb mean dose, Gy       | 45.1 (1.8–71.3)           |
| Bowel Max Dose, Gy (RBE)        | 51.4 (46.0–54.0)          |

*aBased on patients receiving whole pelvis treatment

Maximum dose was kept to < 103% of prescribed dose. Organs at risk (OAR) doses are show in Table 2.

Most patients were treated with two lateral beams. Patients were treated with either uniform scanning (UNS) or PBS (our center switched from UNS to PBS in late-2014), with 1- or 2-fields per day. Patients receiving radiation to the pelvic nodes were treated with 2-fields per day. Patients receiving radiation to prostate without pelvic nodes were initially treated two-fields per day and then our center switched to treating one-field per day as the standard in 2015 (alternating between the two lateral beams every other day). This improved efficiency and was not felt to impact treatment quality. For UNS patients, a 0.8–1.2-cm margin was used to account for penumbra. Wax range compensators were designed with an additional range uncertainty of 2.5% + 2 mm added to the distal and proximal ranges, as well as 1–2-cm smearing margins. These were designed using commercially available Xio treatment planning software (Elekta, Stockholm, Sweden).

Dose was verified with an ion chamber measurement performed in water and field shape was verified by comparing the physical shape of the apertures and compensators with the treatment planning system. For PBS delivery, treatment plans were created using the RayStation treatment planning software (RaySearch Laboratories AB, Stockholm, Sweden) with single-field uniform dose optimization. Dose and...
Results

Patient-reported quality-of-life

Patient reported quality-of-life (QOL) results are detailed in Fig. 1 and Table 3. Urinary function did not change significantly after treatment, as measured by IPSS. Bowel function as measured by EPIC bowel domain scores showed a small decline from 96 at baseline (median) by an average of 5.4 points at 1-year post-treatment (95% CI: 2.5–8.2 points, \( p < 0.001 \)), and then remained stable beyond 1-year (\( p = 0.57 \)). Erectile function as measured by SHIM scores also showed a small decline from 18/25 at baseline (mild ED) by 3.7 points at 1-year post-treatment (95% CI: 1.4–5.9 points, \( p = 0.001 \)). Again, there was no further statistically significant decline beyond 1-year (\( p = 0.25 \)). Treatment with PBS versus UNS did not show a statistically significant difference in toxicity rates, nor did treatment with one-field per day versus two-fields per day.

Genitourinary (GU) toxicity

One grade 3 (GR3) event was seen within the acute window, an episode of gross hematuria that was found on cystoscopy to be likely related to irritation of a scar from previous TURP. In the acute period (<90 days from treatment completion), 86 patients (44.8%) required medication for management of urinary irritation (i.e. anti-inflammatory drugs or anti-α1 adrenoceptor blockers), defined as GR2 toxicity, with two patients requiring intermittent self-catheterization. Majority (61/86 patients) reported resolution of symptoms by 6-months post-treatment, and 73/86 had resolution of symptoms by 18 months. Most common symptoms included frequency (50 patients), urgency (44 patients), and dysuria (24).

Two patients experienced late GR3 GU toxicity, both radiation cystitis presenting with gross hematuria: one patient required hospitalization for cystoscopy although no intervention was ultimately performed and symptoms resolved; the other patient underwent multiple hyperbaric oxygen treatments with eventual resolution of his symptoms. No patients experienced GR 4 or 5 GU toxicity. Actuarial rate of GR2+ GU toxicity at 2-years was 26.4% (95% CI: 19.4–32.9%), mostly consisting of patients remaining on anti-α1-adrenoceptor blockers for urinary symptoms (Fig. 2). Worsening incontinence was seen in 4 patients, three of whom had some leakage pre-treatment. Of the 51 patients with GR2+ late GU toxicity, 21/51 had resolution of their symptoms within 3–6 months, 24/51 had resolution within 18 months, while the rest remained on anti-α1-adrenoceptor blockers at last follow-up.

Univariate analysis (without adjustment for repeated testing) showed a significant correlation between late GR2+ GU toxicity and increased age (HR = 1.50, \( p = 0.004 \)), higher baseline IPSS score (HR = 1.45, \( p = 0.0046 \)) and higher baseline IPSS bother score (HR = 1.35, \( p = 0.016 \)). No statistically significant associations were found with any other clinical features—including alpha blocker use (\( p = 0.19 \)), ADT (\( p = 0.84 \)), or pre-treatment TURP (\( p = 0.14 \))—or dosimetric variables. When \( p \)-values were adjusted for repeated testing, no statistically significant associations were found between toxicity and any variables.

Gastrointestinal (GI) toxicity

One patient experienced late GR3 toxicity, which was managed with admission for transfusion and resolved after argon plasma coagulation. There were no GR 4 or 5 events. In the acute window, 5 patients reported transient GR2 bowel toxicity, mostly in the form of diarrhea and urgency. Late GR2+ bowel toxicity was seen in 34 patients with an actuarial two-year rate of 21.3% (95% CI: 13.9–28.0%) (Fig. 2). Most observed bowel toxicity

Statistical analysis

Statistical computations were performed with R version 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria). Cumulative incidence of toxicity was estimated using the Kaplan-Meier product limit estimator. Univariate Cox proportional hazards regression was used to assess associations of grade 2 or higher (GR2+) toxicity with potential clinical, treatment-related, and dosimetry variables (listed in Tables 1 and 2). The univariate analysis was considered exploratory and hypothesis-generating, so the \( P \)-values were not adjusted to account for the number of comparisons. Changes in QOL scores from before and after treatment were analyzed using generalized estimating equation-based linear regression to account for the repeated measurements per patient. Patients who did not have baseline and at least one follow up QOL responses were excluded from that analysis. Throughout the data analysis, two-sided \( P \) values < 0.05 were considered statistically significant.

fluence were measured pre-treatment using the MatrixxPT ion chamber array device (IBA Dosimetry GmbH, Schwarzenbruck, Germany).

A constant relative biological effectiveness (RBE) factor of 1.1 was used to convert physical dose to RBE adjusted dose. In the present study, CGE and RBE adjusted dose are used interchangeably. The robustness of target and organs at risk (OAR) doses was evaluated by computing the plan with ±3% range uncertainty, as well as simulating setup errors by 3-mm isocenter deviations in the anterior/posterior, superior/inferior, and lateral directions. All patients had daily orthogonal kilovoltage x-rays for image guidance prior to treatment with fiducial localization. A digital imaging positioning system was used to determine optimal table shifts along 3 axes to reproduce fiducial localization within 2 mm of the simulation images. Treatment positioning was re-evaluated if more than 5 min passed before beam availability.
was in the form of transient rectal bleeding (32/39 patients) treated with enemas/suppositories or laser coagulation, with the remaining 7 events were due to isolated rectal discomfort or diarrhea. Of the 32 patients who experienced GR2+ rectal bleeding, all events occurred in the late window. Seventeen received medical management with enemas or suppositories, while 15 underwent argon photocoagulation or electrocautery. Bowel toxicity was associated with anticoagulation use (HR = 3.45, \( p = 0.002 \) without adjustment for repeated testing).

**Erectile dysfunction (ED)**
Actuarial two-year rate of late GR2+ ED was 23.0% (95% CI: 13.8–31.3%) (Fig. 2), defined as worsening ED requiring new medical therapies (e.g. sildenafil, tadalafil, vardenafil), with erections firm enough for penetration after medical therapy. Only two patients reported GR3 ED, defined as poor erectile function not responding to oral or injectable medication; both had baseline ED requiring oral medications. On univariate analysis of ED among men not on androgen deprivation therapy, only younger

**Table 3** Patient-reported QOL results

| QOL Measure | Baseline | Follow Up | Mean Change at 1 Year after Treatment | Mean Annualized Change after 1 Year |
|-------------|----------|-----------|---------------------------------------|-------------------------------------|
|             | No. of Patients | Median (Range) | Mean ± SD | No. of Patients | No. of Visits | Value (95% CI) | P-value | Value (95% CI) | P-value |
| EPIC Bowel  | 164 | 96 (61–100) | 93.4 ± 8.5 | 100 | 183 | −5.4 (−8.2, −2.5) | <0.001 | −1.2 (−5.2, 2.9) | 0.57 |
| IPSS        | 178 | 6 (0–28) | 8.7 ± 6.6 | 130 | 241 | 0.5 (−0.7, 1.8) | 0.40 | −0.5 (−1.9, 1.0) | 0.54 |
| IPSS Bother | 173 | 2 (1–7) | 2.5 ± 1.4 | 125 | 221 | 0.3 (−0.1, 0.7) | 0.12 | −0.2 (−0.6, 0.2) | 0.32 |
| Nocturia    | 181 | 1 (0–8) | 1.8 ± 1.5 | 123 | 217 | 0.3 (−0.0, 0.5) | 0.077 | −0.2 (−0.5, 0.2) | 0.33 |
| SHIM\(^a\)  | 107 | 18 (0–25) | 16.5 ± 7.1 | 66 | 123 | −3.7 (−5.9, −1.4) | 0.001 | 1.8 (−13, 5.0) | 0.25 |

\(^a\)Only assessed in patients not on androgen deprivation therapy
age (HR = 0.6, \( p = 0.022 \) without adjustment for repeated testing) was associated with decreased late GR2+ toxicity. Mean dose to the penile bulb was not significantly associated with erectile dysfunction.

**Hip toxicity**

In the acute window, there were 2 cases of GR2 hip pain requiring anti-inflammatory medication. In the late window, 3 patients reported GR2 hip pain. Three patients reporting maximum GR3 hip pain experienced resolution of symptoms with either cortisone shots to the hip joint, opioid therapy, or eventual hip replacement in one case. The one patient who underwent hip replacement had significant preexisting degenerative changes on pre-treatment imaging. Median time to incidence in those who reported hip pain was 9 months (range 2–29 months). There were no hip fractures. Hip toxicity was not significantly associated with erectile dysfunction.

**Discussion**

This is one of few contemporary studies that evaluates outcomes and toxicity of PBT for localized prostate cancer with prospectively collected data, including patient reported outcomes. This is the largest series to our knowledge that includes patients treated mostly with PBS, which has dosimetric advantages over older passive scattering proton technology in some scenarios [19]. Although PBT offers known dosimetric advantages over photon radiation, especially in the low to intermediate-dose region (such as volume receiving up to 50 Gy), the clinical impact of this is unclear [7, 20].

In our study population, with median follow up of 1.7 years, we found that rates of GR2+ toxicity outcomes were comparable to other reported data. The low rate of GR3 GU toxicity in this study (5/192 patients) is comparable to other evaluations of PBT, with rates generally < 3% [9]. In the largest prospectively captured data of PBT outcomes for prostate cancer to date, Bryant et al. at the University of Florida found a late GR3 GU actuarial 5-year toxicity rate at 2.9% [9]. Prior retrospective studies from this group found 1.0% GR3 GU toxicity [13], while other groups have reported a range of 0–2% [15, 17].

As shown in Table 4, reports including the present study consistently show that the risk of grade 3+ GU and GI toxicity is generally low after both PBT and IMRT [9, 13, 15, 17, 21–24]. However, wide variations can be seen in GR2+ toxicity rates with both IMRT and PBT. For example, in two IMRT studies, GU and GI GR2+ toxicity rates reported by Vora et al. were 24.4% and 10.9% respectively, while Spratt et al. reported rates of 8.5% and 2.0% [22, 23]. Multiple factors illustrated in Table 4 may explain this variability and also make true comparison across standalone studies difficult. First, using RTOG versus CTCAE scoring criteria can significantly impact physician-reported toxicity rates, since RTOG criteria depend on subjective assessments of what qualifies as mild (grade 1) versus moderate (grade 2) toxicity, whereas CTCAE criteria require medical or procedural intervention to qualify as grade 2. Second, many studies report observed toxicity rates (numbers of patients experiencing toxicity) with varying lengths of median follow-up [22–24]. This can be addressed by
comparing actuarial toxicity rates at specific time
intervals, such as 5-years, but these are only inconsist-
ently reported, and at varying time-points themselves
[9, 13, 15, 17, 21]. Third, the dose to which patients
are treated often varies from study to study. Fourth
and finally, treatment planning and patient setup vary
from institution to institution.

There is a clear need for studies that can compare
PBT and IMRT in a standardized fashion. Although level
one evidence comparing IMRT and PBT in patients with
prostate cancer is currently being collected in the
PARTIQoL and COMPPARE trials (NCT01617161,
NCT03561220), results will not be available for years.
Thus far, there is conflicting evidence regarding com-
parative toxicities. In a case-matched comparison of
intensity-modulated radiotherapy (IMRT) or PBT based
treatment matched for age, GI and GU co-morbidity,
and risk group, Fang et al. report that at 2 years there
were no differences in GR2 or higher GU or GI toxicities
[24]. A Medicare-based comparative study found lower
GU toxicity for PBT at 6 months, but no difference at
12 months [18]. Gray et al. compared three dimensional
conformal radiotherapy (3D CRT), IMRT, and PBT and
found worse acute patient-reported QOL for urinary
symptoms for patients treated with 3D CRT but there
were no differences by 2 years [12]. A comparison of
patient-reported QOL after PBT with patient-reported
QOL from the Prostate Cancer Outcomes and Satisfaction
(PROSTQA) treatment assessment study of men treated
with high-dose photon radiation, showed no differences in
any toxicity domain at 2 years [25]. However, a more re-
cent study using private commercial insurance claims
reported that PBT was associated with significant reduc-
tions in urinary toxicity but increased bowel toxicity three
years after treatment [26].

The dosimetric improvement with PBT over IMRT lies
in reductions to low and moderate-dose range exposures
of normal tissue and not high dose range (70–80 Gy),
therefore it is important to qualify the differences that
one might expect from PBT in comparison to IMRT
[20]. Some of these benefits may be recognized as a de-
crease in long term toxicity and changes, including the
risk of secondary malignancy, and will require much lon-
ger follow up with large patient numbers to fully realize
[25]. We found no association of toxicity incidence with
PBS versus UNS technique in our patient cohort. This is
consistent with a previous study that also showed no as-
sociations in a cohort treated with mostly passive scatter,
and some pencil beam technique [15]. Thus, PBS treat-
ment technique may not clinically affect toxicity rates in
prostate cancer treatment, despite potential dosimetric
advantages.

Previous retrospective studies have reported excellent
biochemical outcomes with PBT [9, 17]. At this time,
we did not have enough patient events or follow up time
to comment on control rates in this group. We plan to re-
port updated outcomes in the future as patients accrue
to the registry and follow up data matures.

Limitations of this study include the patient selection
bias for those treated at a single institution. There could
also be a selection bias for those patients who sought ac-
tress to PBT. The follow up period is short, and radiation
toxicity is known to develop years after radiotherapy
[27]. However, we believe the present study is an im-
portant addition to the literature, to assess early outcomes
with modern treatment techniques including daily image
guidance with intraprostatic fiducials and PBS approach.
Strengths include the rigor of prospectively collected
toxicity and outcome data, and data that is both patient
and physician reported. Future analysis will include

| Table 4 Literature review of toxicity data |
|------------------------------------------|
| Study | No. of Patients | Therapy | Median RT Dose Gy or CGE | Median Follow-Up Years | Toxicity Grading Scale | G3+ GU Toxicity | G2+ GU Toxicity | G3+ GI Toxicity | G2+ GI Toxicity |
|-------|----------------|---------|--------------------------|------------------------|------------------------|----------------|----------------|----------------|----------------|
| Liauw et al., 2009 [21] | 130 | IMRT | 76 | 4.4 | RTOG | 6%b | 37.0%b | 5%b | 14.0%b |
| Spratt et al., 2013 [22] | 1002 | IMRT | 86.4 | 5.5 | CTCAE | 2.2% | 8.5% | 0.7% | 2.0% |
| Vora et al., 2013 [23] | 302 | IMRT | 75.6 | 7.6 | CTCAE | 2.6% | 24.4% | 1% | 10.9% |
| Fang et al., 2015 [24] | 94 | IMRT | 79.2 | 3.9 | CTCAE | 0% | 18.3% | 2.1% | 10.8% |
| Fang et al., 2015 [24] | 94 | PS PBT | 79.2 | 2.4 | CTCAE | 2.1% | 12.8% | 0% | 12.8% |
| Slater et al., 2004 [17] | 1255 | PS PBT | 74 | 5.3 | RTOG | 1.0% | – | 1.0% | – |
| Pugh et al., 2013 [15] | 291 | PS > PBS PBT | 76 | 2.0 | RTOG | 0%c | 13.4%c | 0.3%c | 9.6%c |
| Mendenhall et al., 2014 [13] | 211 | PS PBT | 78–82 | 5.2 | CTCAE | 1.0%a | – | 0.5%a | – |
| Bryant et al., 2016 [9] | 1215 | PS PBT | 78 | 5.5 | CTCAE | 2.9%a | – | 0.6%a | – |
| Present study, 2017 | 192 | PBS > PS PBT | 79.2 | 1.7 | CTCAE | 1.0% | 26.4%c | 0.5% | 21.3%c |

Abbreviations: PS passive scatter, PBS pencil beam scanning, PBT proton beam therapy, IMRT intensity-modulated radiation therapy, RTOG radiation therapy oncology group, CTCAE common terminology criteria for adverse events, version 4.0

\(a = 5\text{-year actuarial rate, } b = 4\text{-year actuarial rate, } c = 2\text{-year actuarial rate.} \)

No symbol next to a toxicity rate % indicates a rate reported as the number of toxicity events observed over the total number of patients, with varying median follow-up across studies.
continued patient accrual with longer median follow up. The larger patient numbers will allow us to better assess late treatment toxicities and PSA trends amongst patients treated with PBT for prostate cancer at our institution.

Conclusions
We report toxicity rates in patients treated with contemporary PBT techniques (mostly PBS) at our institution with median 1.7 years of follow up. Grade 3+ toxicities were rare. Patient reported quality-of-life are excellent, with no change in urinary function post-radiation, and small declines in erectile function and bowel QOL by 1-year post-treatment. Larger patient numbers and longer follow up are anticipated to add robustness to our data.

Abbreviations
CGE: Cobalt gray equivalent; CI: Confidence interval; CT: Computed tomography; CTCAE: Common Terminology Criteria for Adverse Events; CTV: Clinical target volume; ED: Erectile dysfunction; EPIC: Expanded Prostate Cancer Index Composite; GI: Gastrointestinal; GR2: Grade 2; GR2+: Grade 2 or higher; GR3: Grade 3; GR4: Grade 4; GU: Genitourinary; Gy: Gray; HR: Hazard ratio; IMRT: Intensity-modulated radiotherapy; IPSS: International Prostate Symptom Score; IRB: Institutional review board; MRT: Magnetic resonance imaging; OAR: Organs at risk; PBS: Pencil beam scanning; PBT: Proton beam therapy; PS: Passive scatter; PSA: Prostate specific antigen; PTV: Planning target volume; QOL: Quality of life; RBE: Relative biological effectiveness; SHIM: Sexual Health Inventory for Men; UDS: Uniform scanning; US: Ultrasound

Acknowledgments
The authors would like to acknowledge Jordan Dickson BA and Prachie Banthia BA, who assisted in the formatting of blinded datasets containing results from our patient database.

Funding
Study data were collected and managed using REDCap electronic data capture tools hosted at the University of Washington, supported by Institute of Translational Health Science (ITHS) grant support (UL1 TR002319 from NCATS/NIH).

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
HJL and MWM contributed equally to this work and share first authorship. HJL, MWM, MBS, and AF performed the data collection. SRB and DSH contributed to the data analysis. JZ was responsible for the design of this study. All authors contributed to the writing, approved the final manuscript, and have given approval for the manuscript to be published.

Ethics approval and consent to participate
All patients were enrolled on a prospective University of Washington IRB approved registry and gave written consent for their participation.

Consent for publication
Not applicable. All patient information has been thoroughly de-identified.

Competing interests
Mr. Hippe reports grants from the NIH/NCI, and Dr. Russell reports a scientific advisory position with Varian Medical Corporation during the conduct of this study. All remaining authors of this publication declare no competing interest.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Duke University School of Medicine, 10 Duke Medicine Circle, Durham, NC 27710, USA. 2Department of Radiation Oncology, University of Washington School of Medicine, 1959 NE Pacific Street, Campus, Box 356043, Seattle, WA 98195, USA. 3Department of Radiology, University of Washington School of Medicine, 1959 NE Pacific Street, Campus, Box 357115, Seattle, WA 98195, USA. 4Seattle Cancer Care Alliance Proton Therapy Center, 1570 N 115th St, Seattle, WA 98115, USA.

Received: 27 June 2018 Accepted: 6 September 2018
Published online: 17 September 2018

References
1. Handy FC, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016;375(15):1415–24.
2. Chen L, et al. Comparison on efficacy of radical prostatectomy versus external beam radiotherapy for the treatment of localized prostate cancer. Oncotarget. 2017;8(45):79854–63.
3. Chen RC, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate Cancer. JAMA. 2017;317(11):1141–50.
4. Potosky AL, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96(18):1358–67.
5. Wolf RF, et al. A systematic review of randomised controlled trials of radiotherapy for localized prostate cancer. Eur J Cancer. 2015;55(16):2345–67.
6. Zietman AL, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010;28(7):1106–11.
7. Trofimov A, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007;69(2):444–53.
8. Tepper JE. Protons and parachutes. J Clin Oncol. 2008;26(15):2436–7.
9. Bryant C, et al. Five-year biochemical results, toxicity, and patient-reported quality of life after delivery of dose-escalated image guided proton therapy for prostate Cancer. Int J Radiat Oncol Biol Phys. 2016;95(1):422–34.
10. Coen JJ, et al. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. Int J Radiat Oncol Biol Phys. 2011;81(4):1005–9.
11. Colaco RJ, et al. Rectal toxicity after proton therapy for prostate cancer: an analysis of outcomes of prospective studies conducted at the university of Florida proton therapy institute. Int J Radiat Oncol Biol Phys. 2015;91(1):172–81.
12. Gray PJ, et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013;119(9):1729–35.
13. Mendenhall NP, et al. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014;88(3):596–602.
14. Nihei K, et al. Multi-institutional phase II study of proton beam therapy for organ-confined prostate cancer: focusing on the incidence of late rectal toxicities. Int J Radiat Oncol Biol Phys. 2011;81(2):390–6.
15. Pugh TJ, et al. Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;87(5):946–53.
16. Sheets NC, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307(15):1611–20.
17. Slater JD, et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004;60(2):348–52.
18. Yu JB, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013;105(1):25–32.
19. Yeung D, McKenzie C, Indelicato DJ. A dosimetric comparison of intensity-modulated proton therapy optimization techniques for pediatric craniopharyngiomas: a clinical case study. Pediatr Blood Cancer. 2014;61(1):89–94.

20. Vargas C, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(3):744–51.

21. Liauw SL, et al. Biochemical control and toxicity after intensity-modulated radiation therapy for prostate Cancer. Technol Cancer Res Treat. 2009;8(3):201–6.

22. Spratt DE, et al. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(3):686–92.

23. Vora SA, et al. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer. J Urol. 2013;190(2):521–6.

24. Fang P, et al. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. Cancer. 2015;121(7):1118–27.

25. Hoppe BS, Bryant C, Sandler HM. Radiation for prostate cancer. intensity modulated radiation therapy versus proton beam. J Urol. 2015;193(4):1089–91.

26. Pan HY, et al. Comparative toxicities and cost of intensity-modulated radiotherapy, proton radiation, and stereotactic body radiotherapy among younger men with prostate Cancer. J Clin Oncol. 2018;36(18):1823–30.

27. Gardner BG, et al. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol. 2002;167(1):123–6.